Medigene Ag (MDGEF) 11.8000 $MDGEF Seeking Alpha's

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Medigene Ag (MDGEF) 11.8000 $MDGEF

Seeking Alpha's Biotech Weekly: Biogen's Plaque Attack, Amgen Or Gilead?, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 20, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
TRVN: 6.87 (-0.05), MDT: 76.42 (+0.16), CLDX: 25.81 (+0.06), FOMX: 11.41 (+0.09), AMGN: 162.36 (+0.38), AET: 112.74 (+1.26), NKTR: 11.13 (+0.20), CELG: 115.53 (+0.45), HUM: 175.90 (+1.65), CANF: 2.33 (-0.01), ANTM: 161.37 (+1.37), NVO: 56.75 (+0.06), GILD: 109.30 (+0.56), GERN: 3.89 (-0.02), AZN: 69.29 (-0.81), CLLS: 32.25 (+0.86), WCG: 83.22 (+0.65), FOLD: 10.53 (+0.03), REGN: 489.01 (-2.42), CUR: 1.70 (-0.04)

Medigene AG: Addressing The CAR-T Market Pain Points
Decision Analytics - Seeking Alpha - Wed Mar 18, 11:51AM CDT
I have written about the market opportunity for adoptive cancer immunotherapy before when my interest was piqued by the incredible appreciation of a number of early-stage CAR-T therapy companies (a form of adoptive immunotherapy). Companies such as...
MDVN: 122.90 (-0.47), JNJ: 102.30 (+0.47), ZIOP: 9.17 (-0.17), BLCM: 23.02 (-1.37), KITE: 50.02 (-2.24), JUNO: 43.37 (-1.52), NVS: 103.75 (-0.15)

Primary Biliary Cirrhosis Therapeutics Pipeline Review 2015 - 9 Companies & 10 Drug Profiles
M2 - Tue Mar 03, 6:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/h7976j/primary_biliary) has announced the addition of the "Primary Biliary Cirrhosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Primary Biliary Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Primary Biliary Cirrhosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlbireoPharma - Dr. Falk Pharma GmbH - GlaxoSmithKline plc - Intercept Pharmaceuticals, Inc. - Johnson & Johnson - MediGene AG - NGM Biopharmaceuticals, Inc. - Shire Plc - Virobay Inc. Drug Profiles - A-4250 - budesonide - FFP-104 - GSK-2330672 - NGM-282 - obeticholic acid - RhuDex - SHP-625 - ustekinumab - VBY-825 For more information visit http://www.researchandmarkets.com/research/h7...ry_biliary
JNJ: 102.30 (+0.47), SHPG: 254.45 (+3.99), ICPT: 306.23 (-0.84), VBAY: (), GSK: 44.77 (-0.22)

Biliary Cirrhosis Therapeutic Pipeline Review H2 2014 Report at ReportsnReports.com
PRWeb - Mon Jan 05, 1:30PM CST
The report "Biliary Cirrhosis - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Biliary Cirrhosis. Primary biliary cirrhosis is a long-term liver disease in which the bile ducts in the liver become damaged. It is most likely an autoimmune disease, where the body's immune system attacks its own cells. It generally strikes women between the ages of 40 and 60. Symptoms of Primary biliary cirrhosis include the following Fatigue, Pruritus, Right upper quadrant discomfort, Hepatomegaly, Hyperpigmentation, Splenomegaly, Jaundice, Xanthelasmata, Sicca syndrome and Kayser-Fleischer rings. Treatment for primary biliary cirrhosis is difficult, because the immune system appears to be involved. Complete Report is Available @ http://www.reportsnreports.com/reports/322822...-2014.html
JNJ: 102.30 (+0.47), SHPG: 254.45 (+3.99), ICPT: 306.23 (-0.84), VBAY: (), GSK: 44.77 (-0.22)

Global Cervical Cancer Therapeutic Pipeline Review, H2 2014 - 35 Companies & 71 Drug Profiles
M2 - Wed Nov 19, 4:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/4p52hn/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - Nektar Therapeutics - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Amorfix Life Sciences Ltd. - MediGene AG - Nanotherapeutics, Inc. - Arbor Vita Corporation - Novartis AG - Chong Kun Dang Pharmaceutical Corp. - Taiho Pharmaceutical Co., Ltd. - Zeria Pharmaceutical Co Ltd - Genmab A/S - Advaxis, Inc. - 3SBio Inc. - Transgene SA - Antigen Express, Inc. - Shantha Biotechnics Limited - Bionor Pharma ASA - Azaya Therapeutics Incorporated - Merrimack Pharmaceuticals, Inc. - Genexine, Inc. - Genticel - Sirnaomics, Inc. - EyeGene, Inc. - Vaccibody AS - Wellstat Biologics Corporation - ISA Pharmaceuticals B.V. For more information visit http://www.researchandmarkets.com/research/4p...cal_cancer
MACK: 12.66 (+0.34), INO: 7.97 (-0.02), ADXS: 20.08 (+1.11), GSK: 44.77 (-0.22), NKTR: 11.13 (+0.20), NVS: 103.75 (-0.15)

T-Cell Leukemia Therapeutics Pipeline Review 2014 - 15 Drug Profiles from 10 Leading Pharma Companies
M2 - Wed Sep 10, 10:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/shcdvv/tcell_leukemia) has announced the addition of the "T-Cell Leukemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for T-Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Kyowa Hakko Kirin Co., Ltd. - Sanofi - MediGene AG - Nippon Kayaku Co., Ltd. - Pfizer Inc. - Celgene Corporation - Pharmacyclics, Inc. - Stemline Therapeutics, Inc. - Applied Immune Technologies Ltd Drug Profiles - alemtuzumab - mogamulizumab - lenalidomide - PF-03084014 - BMS-906024 - PCI-34051 - NK-314 - Recombinant Protein for CNS, Oncology, Hematological Disorders and Metabolic Disorders - Anti-TCR Monoclonal Antibodies for Leukemia and Autoimmune Disease - MMIG-202 - INA-01 - SL-101 - Antibody Targeting HLA-A2 for Neurology, Infectious Diseases and Oncology - Synthetic Peptide for Oncology and Male health - Cell Therapy to Target CD38 for cancer For more information visit http://www.researchandmarkets.com/research/sh...l_leukemia
PCYC: 255.42 (-0.50), PFE: 33.99 (+0.05), BMY: 67.64 (+0.19), STML: 13.43 (-0.17), CELGZ: 2.60 (-0.10)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sokin’s UAE License Turns Expansion Into Real Payments Plumbing

Updated Category News Views 97

Dubai expansion headlines are cheap; regulated local money movement is not. That is why Sokin’s newly approved Dubai Financial Services Authority license deserves more than the usual fintech applause line. The company has paired that approval with AED accounts, local payment rails, a One Za’abeel office and a plan to double its UAE staff over the next year. None of...

Continue Reading
Marelli’s Two Awards Put Practical Auto Tech in Focus

Updated Category News Views 43

Two trophies in Novi do not fill an order book, but Marelli’s latest pair says something useful about where automotive suppliers are trying to earn their keep. The company collected a 2026 Automotive News PACE Award for HorizonView and a PACE Pilot Award for Affordable 5G RedCap at the November 17 ceremony. One is already deployed in production; the other is a...

Continue Reading
LONGi's Solar-Storage Push Faces Africa's Cost Wall

Updated Category News Views 75

A vaccine refrigerator humming through a blackout is more meaningful than another climate-conference slogan. That was the useful thread running through LONGi's November 13 COP31 side event in Antalya, Türkiye: solar and storage are not merely hardware for remote communities. When designed, financed and maintained properly, they can keep clinics, water pumps and other...

Continue Reading
Sysco's Northern California Labor Deal Gets Bigger

Updated Category News Views 0

One hundred forty-four drivers may not rattle a giant food distributor by themselves, but labor agreements have a habit of growing legs. Sysco's Northern California and Nevada regional contract has added members from Teamsters Locals 386 and 431, bringing its coverage above 1,100 workers. For investors watching Sysco, this is less about one afternoon's headline and more...

Continue Reading
Sunbit’s 2027 Loan Push Meets an NVIDIA-Fueled Tape

Updated Category News Views 116

Credit Is About to Enter Sunbit’s Growth Story Sunbit has spent years building a point-of-sale fintech footprint, and the numbers it cited on November 18 make the next step harder to dismiss as mere marketing fluff. The company says it has topped 400,000 activated cardholders and 50,000 merchants, while expecting more than $440 million in fiscal 2026 sales on greater...

Continue Reading
Precision Metal Forming Is Industry's Quiet Backbone

Updated Category News Views 72

A fraction of a millimeter can turn a perfectly good industrial part into an expensive headache. That unglamorous reality sits at the center of Michele Caulfield's discussion of precision metal forming for HelloNation, and it deserves more attention than it usually gets. Investors watching manufacturing tend to chase flashy automation headlines, big aerospace orders, or...

Continue Reading
Envision and Tai Tam Put 45 MW Wind Bet to Work in Vietnam

Updated Category News Views 177

A wind site averaging 6.5 meters per second can look unremarkable on a map, yet that is precisely where equipment choices start separating serious developers from brochure merchants. Envision Energy and Vietnam's Tai Tam Group are taking that test on with the 45 MW Phuoc Dan wind project in Khanh Hoa Province. The arrangement follows five years of cooperation, but the...

Continue Reading
Three Cash Buyouts Draw Fresh Shareholder Scrutiny

Updated Category News Views 149

Three cash-price tags landed on the tape with a lawyerly asterisk attached: are public holders actually getting a fair shake? On November 18, 2026, Halper Sadeh LLC said it was investigating proposed sales involving Surgery Partners, Braze and CCC Intelligent Solutions. That is not a finding of misconduct, and investors ought to keep that distinction bolted firmly to the...

Continue Reading
Marina del Rey's Travel Award Brings Fresh Attention

Updated Category News Views 39

A harbor town just got handed a useful little megaphone. On November 18, 2026, the Marina del Rey Tourism Board said Marina del Rey had been selected as a winner in Good Housekeeping's 2027 Travel Awards. That is not a quarterly earnings event, and nobody ought to dress it up as one. Still, in the visitor economy, recognition from a broad consumer publication can matter...

Continue Reading
Berlin Heals Puts Microcurrent Therapy to a Real Test

Updated Category News Views 34

A silent electrical signal is heading into the sort of trial that separates intriguing ideas from credible medical evidence. Berlin Heals Holding AG has initiated C-MIC IV, an international randomized, double-blind, sham-controlled study of its implanted microcurrent therapy for symptomatic heart failure. The first patient has already been implanted in Kragujevac, Serbia....

Continue Reading

Top 5 Most Recently Viewed Articles

Tecsys Applauds 2026 Supply Chain Trailblazers

Updated Category News Views 26

Celebrating Supply Chain Game-Changers Diving headfirst into the world of supply chains at Tecsys's signature event, the User Conference in Nashville, showcased this year's champions who took the bull by the horns. These aren’t mere button pushers. They’re the powerhouses of healthcare and distribution, pushing operational performance to new heights. Driving Supply...

Continue Reading
Key Insights on Icelandic Salmon's Upcoming Q2 Results Webinar

Updated Category News Views 129

Exciting Presentation of Icelandic Salmon's Q2 Results Icelandic Salmon is gearing up to unveil its second quarter results for 2025. This exciting upcoming event is slated to take place on a Thursday via a Teams webinar, providing a platform for a detailed overview of the company's performance. Details of the Presentation Hosted by the esteemed CEO Bjørn Hembre alongside...

Continue Reading
TRG Screen Launches Xmon AI Assist for Enhanced Data Insights

Updated Category News Views 225

Revolutionizing Data Management with AI Technology In today's fast-paced financial landscape, organizations are constantly seeking tools that streamline operations and enhance decision-making capabilities. TRG Screen has risen to the occasion with the introduction of Xmon AI Assist, a cutting-edge innovation designed to transform how financial institutions manage their...

Continue Reading
Crypto Analyst Raoul Pal Discusses the Current Banana Zone Trends

Updated Category News Views 379

Raoul Pal’s Insights on the Current Crypto Market U.Today - Raoul Pal, the founder and CEO of Real Vision, is widely recognized for his expertise in cryptocurrency and investing. Recently, he took to the social media platform X (formerly known as Twitter) to engage with his followers about the prevailing conditions in the crypto market and the future outlook for...

Continue Reading
Investing $1000 in Gold Fields: A 5-Year Growth Journey

Updated Category News Views 230

The Incredible Return on Gold Fields Investment Gold Fields (NYSE: GFI) has remarkably outperformed the market in the past five years, showcasing an annualized return of 27.98%—a substantial difference over standard investment returns. With a current market capitalization of $38.14 billion, Gold Fields stands out as a worthwhile investment opportunity. What If You...

Continue Reading